University Hospital Schleswig Holstein Klinikum Bad Bramstedt

Bad Bramstedt, Germany

University Hospital Schleswig Holstein Klinikum Bad Bramstedt

Bad Bramstedt, Germany

Time filter

Source Type

Holle J.U.,University Hospital Schleswig Holstein Klinikum Bad Bramstedt | Dubrau C.,University Hospital Schleswig Holstein Klinikum Bad Bramstedt | Herlyn K.,University Hospital Schleswig Holstein Klinikum Bad Bramstedt | Heller M.,University of Kiel | And 4 more authors.
Annals of the Rheumatic Diseases | Year: 2012

Objective: First, to investigate the overall efficacy and safety of rituximab (RTX) in refractory granulomatosis with polyangiitis (GPA) in a tertiary referral centre. Second, to compare the efficacy of RTX in granulomatous and vasculitic manifestations in GPA. Patients and methods: This study comprised a retrospective, standardised data collection from all patients who received RTX for refractory Wegener's granulomatosis from 2002 to 2010. Patients were assessed by a standardised interdisciplinary diagnostic procedure (including ear, nose and throat and ophthalmology assessment, MRI, immunodiagnostics, B-cell levels and Birmingham Vasculitis Activity Score) and were treated by standardised therapeutic regimens according to available evidence. Results: 59 patients received 75 cycles of RTX. 9.3% achieved complete remission. A response was documented in 61.3% (improvement in 52%, unchanged disease activity in 9.3%), 26.7% had refractory disease. Birmingham Vasculitis Activity Score, disease extent index, erythrocyte sedimentation rate, C-reactive protein and prednisolone demand decreased significantly. All patients achieved B-cell depletion. Granulomatous manifestations such as orbital granuloma and pachymeningitis were more frequently refractory to RTX than vasculitis or other granulomatous manifestations. Thus, for example, complete remission/improvement was found in 89.2% of patients with renal disease and in only 44.4% of those with orbital masses (p=0.003). The relapse rate was 44.4% after a median period of 13.5 months. Adverse events occurred in 29%, pneumonia in 15% and death in 3%. Conclusion: The overall response rate of refractory GPA to RTX was high (61.3% complete remission or improvement). Response rates of vasculitic manifestations were excellent; failure of response/ progress was mostly due to granulomatous manifestations, especially orbital masses. Relapse rates were high (40%) despite maintenance treatment.

Loading University Hospital Schleswig Holstein Klinikum Bad Bramstedt collaborators
Loading University Hospital Schleswig Holstein Klinikum Bad Bramstedt collaborators